Association of MGLL Intronic C>T Single Nucleotide Polymorphism (rs782440) with Borderline Personality Disorder: A Case-Control Study

Document Type : Original Article


1 Department of Neuroscience, School of Advanced Medical Sciences and Technologies, Hamadan University of Medical Sciences, Hamadan, Iran

2 Department of Psychiatry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

3 Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

4 Noncommunicable Diseases Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

5 Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Hamadan University of Medical Sciences, Hamadan, Iran

6 Neurophysiology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran


Objective: From the perspective of etiology, borderline personality disorder (BPD) is a multifactorial and complex
disorder, hence our understanding about the molecular basis and signaling of this disorder is extremely limited.
The purpose of this study was evaluating the relationship between BPD and the Monoacylglycerol lipase (MGLL)
polymorphism rs782440 in the population of Hamadan, Iran.
Materials and Methods: In this case-control study, 106 participants including 53 patients with BPD and 53
healthy control subjects were selected by psychiatrists in the Department of Psychiatry at Farshchian Sina
Hospital in Hamadan. The BPD patients were selected based on the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5) form for diagnosing BPD patients. For genotyping, polymerase chain reaction (PCR) was
used to amplify the desired region including the MGLL intronic C>T single nucleotide polymorphism (SNP)
(rs782440) and afterward the amplicon was sequenced using the Sanger sequencing method. To determine the
genotype of these patients, their sequences were aligned with the reference sequence of MGLL through the CLC
genomic workbench software.
Results: The results indicated that the frequency of TT in comparison to the CC genotype was significantly different
(P=0.003) and the risk of BPD in change from the TT genotype to CC genotype was increased by 6.679%. Regarding
the frequency of allele in this group, no significant difference was observed.
Conclusion: This paper, has studied and reports for the first time, the association between MGLL SNP (rs782440) with
BPD. The findings of the current research revealed that the TT genotype increases the risk of BPD compared to the CC
genotype. Considering the lack of a suitable diagnostic biomarker for BPD, using this potential biomarker in the near
future can be promising.


Main Subjects

  1. Chanen AM, Betts JK, Jackson H, Cotton SM, Gleeson J, Davey CG, et al. A comparison of adolescent versus young adult outpatients with first-presentation borderline personality disorder: findings from the MOBY randomized controlled trial. Can J Psychiatry. 2022; 67(1): 26-38.
  2. Kaplan B, Yazici Gulec M, Gica S, Gulec H. The association between neurocognitive functioning and clinical features of borderline personality disorder. Braz J Psychiatry. 2020; 42(5): 503-509.
  3. Mulder RT, Newton-Howes G, Crawford MJ, Tyrer PJ. The central domains of personality pathology in psychiatric patients. J Pers Disord. 2011; 25(3): 364-377.
  4. Lubke GH, Laurin C, Amin N, Hottenga JJ, Willemsen G, van Grootheest G, et al. Genome-wide analyses of borderline personality features. Mol Psychiatry. 2014; 19(8): 923-929.
  5. Siever LJ, Torgersen S, Gunderson JG, Livesley WJ, Kendler KS. The borderline diagnosis III: identifying endophenotypes for genetic studies. Biol Psychiatry. 2002; 51(12): 964-968.
  6. Aliczki M, Varga ZK, Balogh Z, Haller J. Involvement of 2-arachidonoylglycerol signaling in social challenge responding of male CD1 mice. Psychopharmacology (Berl). 2015; 232(12): 2157-2167.
  7. Bhatia G, Bansal V, Harismendy O, Schork NJ, Topol EJ, Frazer K, et al. A covering method for detecting genetic associations between rare variants and common phenotypes. PLoS Comput Biol. 2010; 6(10): e1000954.
  8. McAllister LA, Butler CR, Mente S, O’Neil SV, Fonseca KR, Piro JR, et al. Discovery of trifluoromethyl glycol carbamates as potent and selective covalent monoacylglycerol lipase (MAGL) inhibitors for treatment of neuroinflammation. J Med Chem. 2018; 61(7): 3008- 3026.
  9. Grabner GF, Eichmann TO, Wagner B, Gao Y, Farzi A, Taschler U, et al. Deletion of monoglyceride lipase in astrocytes attenuates lipopolysaccharide-induced neuroinflammation. J Biol Chem. 2016; 291(2): 913-923.
  10. Bedse G, Bluett RJ, Patrick TA, Romness NK, Gaulden AD, Kingsley PJ, et al. Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors. Transl Psychiatry. 2018; 8(1): 92.
  11. Ogawa S, Kunugi H. Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase: new targets for future antidepressants. Curr Neuropharmacol. 2015; 13(6): 760-775.
  12. Wang Y, Gu N, Duan T, Kesner P, Blaskovits F, Liu J, et al. Monoacylglycerol lipase inhibitors produce pro- or antidepressant responses via hippocampal CA1 GABAergic synapses. Mol Psychiatry. 2017; 22(2): 215-226.
  13. Kolla NJ, Mizrahi R, Karas K, Wang C, Bagby RM, McMain S, et al. Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [11C]CURB positron emission tomography study. Neuropsychopharmacology. 2020; 45(11): 1834- 1841.
  14. Izzo NJ, Yuede CM, LaBarbera KM, Limegrover CS, Rehak C, Yurko R, et al. Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer’s disease modification. Alzheimers Dement. 2021; 17(8): 1365-1382.
  15. Moradi S, Tapak L, Afshar S. Identification of novel noninvasive diagnostics biomarkers in the parkinson’s diseases and improving the disease classification using support vector machine. Biomed Res Int. 2022; 2022: 5009892.
  16. Salem E, Keshvari A, Mahdavinezhad A, Soltanian AR, Saidijam M, Afshar S. Role of EFNA1 SNP (rs12904) in tumorigenesis and metastasis of colorectal cancer: a bioinformatic analysis and HRM SNP genotyping verification. Asian Pac J Cancer Prev. 2022; 23(10): 3523-3531.
  17. Ando T, Tamura N, Mera T, Morita C, Takei M, Nakamoto C, et al. Association of the c.385C>A (p.Pro129Thr) polymorphism of the fatty acid amide hydrolase gene with anorexia nervosa in the Japanese population. Mol Genet Genomic Med. 2014; 2(4): 313-318.
  18. Lazary J, Eszlari N, Juhasz G, Bagdy G. A functional variant of CB2 receptor gene interacts with childhood trauma and FAAH gene on anxious and depressive phenotypes. J Affect Disord. 2019; 257: 716-722.
  19. Palmer RHC, McGeary JE, Knopik VS, Bidwell LC, Metrik JM. CNR1 and FAAH variation and affective states induced by marijuana smoking. Am J Drug Alcohol Abuse. 2019; 45(5): 514- 526.
  20. Ouellette C, Rudkowska I, Lemieux S, Lamarche B, Couture P, Vohl MC. Gene-diet interactions with polymorphisms of the MGLL gene on plasma low-density lipoprotein cholesterol and size following an omega-3 polyunsaturated fatty acid supplementation: a clinical trial. Lipids Health Dis. 2014; 13: 86.
  21. Joyce PR, Stephenson J, Kennedy M, Mulder RT, McHugh PC. The presence of both serotonin 1A receptor (HTR1A) and dopamine transporter (DAT1) gene variants increase the risk of borderline personality disorder. Front Genet. 2014; 4: 313.
  22. Iwasaki S, Ishiguro H, Higuchi S, Onaivi ES, Arinami T. Association study between alcoholism and endocannabinoid metabolic enzyme genes encoding fatty acid amide hydrolase and monoglyceride lipase in a Japanese population. Psychiatr Genet. 2007; 17(4): 215-220.
  23. Tardelli M. Monoacylglycerol lipase reprograms lipid precursors signaling in liver disease. World J Gastroenterol. 2020; 26(25): 3577-3585.
  24. Newton-Howes G, Clark LA, Chanen A. Personality disorder across the life course. Lancet. 2015; 385(9969): 727-734.
  25. Zanarini MC, Frankenburg FR, Reich DB, Conkey LC, Fitzmaurice GM. Treatment rates for patients with borderline personality disorder and other personality disorders: a 16-year study. Psychiatr Serv. 2015; 66(1): 15-20.
  26. Amad A, Ramoz N, Peyre H, Thomas P, Gorwood P. FKBP5 gene variants and borderline personality disorder. J Affect Disord. 2019; 248: 26-28.
  27. Zhang M, Liu N, Chen H, Zhang N. Oxytocin receptor gene, childhood maltreatment and borderline personality disorder features among male inmates in China. BMC Psychiatry. 2020; 20(1): 332.
  28. Kolla NJ, Meyer J, Sanches M, Charbonneau J. Monoamine oxidase- a genetic variants and childhood abuse predict impulsiveness in borderline personality disorder. Clin Psychopharmacol Neurosci. 2017; 15(4): 343-351.
  29. Salinas V, Villarroel J, Silva H, Herrera L, Jerez S, Zazueta A, et al. SERT and BDNF polymorphisms interplay on neuroticism in borderline personality disorder. BMC Res Notes. 2020; 13(1): 61.
  30. Hohmann AG. Inhibitors of monoacylglycerol lipase as novel analgesics. Br J Pharmacol. 2007; 150(6): 673-675.
  31. Li X, Gao S, Li W, Liu Z, Shi Z, Qiu C, et al. Effect of monoacylglycerol lipase on the tumor growth in endometrial cancer. J Obstet Gynaecol Res. 2019; 45(10): 2043-2054.
  32. Muldoon PP, Chen J, Harenza JL, Abdullah RA, Sim-Selley LJ, Cravatt BF, et al. Inhibition of monoacylglycerol lipase reduces nicotine withdrawal. Br J Pharmacol. 2015; 172(3): 869-882.
  33. Harismendy O, Bansal V, Bhatia G, Nakano M, Scott M, Wang X, et al. Population sequencing of two endocannabinoid metabolic genes identifies rare and common regulatory variants associated with extreme obesity and metabolite level. Genome Biol. 2010; 11(11): R118.
  34. Rao P, Zhou Y, Ge SQ, Wang AX, Yu XW, Alzain MA, et al. Validation of type 2 diabetes risk variants identified by genome-wide association studies in Northern Han Chinese. Int J Environ Res Public Health. 2016; 13(9): 863.
  35. Wong BS, Camilleri M, Busciglio I, Carlson P, Szarka LA, Burton D,et al. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011; 141(5): 1638-1647. e1-7.
  36. Müller TD, Reichwald K, Brönner G, Kirschner J, Nguyen TT, Scherag A, et al. Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa. Child Adolesc Psychiatry Ment Health. 2008; 2(1): 33.
  37. Bourdy R, Hertz A, Filliol D, Andry V, Goumon Y, Mendoza J, et al. The endocannabinoid system is modulated in reward and homeostatic brain regions following diet-induced obesity in rats: a cluster analysis approach. Eur J Nutr. 2021; 60(8): 4621-4633.
  38. Tagliamonte S, Laiola M, Ferracane R, Vitale M, Gallo MA, MeslierV, et al. Mediterranean diet consumption affects the endocannabinoid system in overweight and obese subjects: possible links with gut microbiome, insulin resistance and inflammation. Eur J Nutr. 2021; 60(7): 3703-3716.
  39. Gil-Ordóñez A, Martín-Fontecha M, Ortega-Gutiérrez S, López- Rodríguez ML. Monoacylglycerol lipase (MAGL) as a promising therapeutic target. Biochem Pharmacol. 2018; 157: 18-32.
  40. Carey CE, Agrawal A, Zhang B, Conley ED, Degenhardt L, Heath AC, et al. Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. J Abnorm Psychol. 2015; 124(4): 860-877.